Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)

ABSTRACT Background and objective: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays important role in tumour growth with ongoing research regarding its role as a prognostic factor and also targeted anti-angiogenic therapeutic agent in thyroid cancer. VEGF is known to hav...

Full description

Bibliographic Details
Main Author: Razy, Nur Hidayati Mohamad Pakarul
Format: Thesis
Language:English
Published: 2017
Subjects:
Online Access:http://eprints.usm.my/45422/1/Dr.%20Nurhidayati%20Mohamad%20Pakarul%20Razy-24%20pages.pdf
_version_ 1797011374350532608
author Razy, Nur Hidayati Mohamad Pakarul
author_facet Razy, Nur Hidayati Mohamad Pakarul
author_sort Razy, Nur Hidayati Mohamad Pakarul
collection USM
description ABSTRACT Background and objective: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays important role in tumour growth with ongoing research regarding its role as a prognostic factor and also targeted anti-angiogenic therapeutic agent in thyroid cancer. VEGF is known to have high affinity to VEGF receptors such as VEGFR-1 (Flt-1) and VEGFR-2 (KDR) and their co-expression in pathological condition had been demonstrated in previous studies. Papillary thyroid carcinoma (PTC) is the most common differentiated thyroid cancer and studies showed the increasing incidence of carcinoma arising in multinodular goitre (MNG). The aim of the current study to determine the expression of VEGF and VEGF receptors (VEGFR) in thyroid nodular hyperplasia and PTC. Materials and methods: We conducted a cross sectional study based on retrieved paraffinized archival tissue blocks of 113 nodular hyperplasia and 67 PTC from the thyroidectomy specimens from the year of 2003 to 2014.The tissue sections were then stained by immunohistochemistry for VEGF, VEGFR-1 and VEGFR-2. The lymph node involvement and extrathyroid extension also were determined. Results: The mean age of PTC patients was 44.7 ± 15.8years and nodular hyperplasia subjectswere42.2 ± 13.6years. Female gender predominate in both benign nodular hyperplasia and PTC with, 86% (97 out of 113) and 78% (52 out of67) respectively. There was a statistical difference of VEGFR-1 (p=0.028) andVEGFR-2 (p=0.003) expression between nodular hyperplasia and PTC. However, no significant difference of VEGF expression (p=0.576) between both diseases. Co-expression of VEGF and VEGFR-1 was significant in both nodular hyperplasia (p=0.016) and papillary thyroid carcinoma (p=0.03), meanwhile no relevant relationship for VEGF and VEGFR-2 expression (p>0.05). The patients were further divided into young age group (<45 years old) and older age group (≥45 years old). Most of the subjects positive for lymph node metastasis and had extrathyroid extension were female and from older age group. From 15 lymph nodes with metastasis, 60% (9/15) were female and 53% (8/15) from older age group. All two cases that showed extrathyroid extension were from older age group and female. However, there was no significant association (p>0.05) between lymph node status and extrathyroid extension with age groups, gender, VEGF and VEGFR expression. Conclusions: VEGF, VEGFR-1 and VEGFR-2 showed overexpression in both benign thyroid nodular hyperplasia and PTC. The expression of VEGFR-1 and VEGFR-2 more significant in PTC with relevant co-expression of VEGF and VEGFR-1.
first_indexed 2024-03-06T15:33:25Z
format Thesis
id usm.eprints-45422
institution Universiti Sains Malaysia
language English
last_indexed 2024-03-06T15:33:25Z
publishDate 2017
record_format dspace
spelling usm.eprints-454222020-10-22T03:03:15Z http://eprints.usm.my/45422/ Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC) Razy, Nur Hidayati Mohamad Pakarul RC648-665 Diseases of the endocrine glands. Clinical endocrinology ABSTRACT Background and objective: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays important role in tumour growth with ongoing research regarding its role as a prognostic factor and also targeted anti-angiogenic therapeutic agent in thyroid cancer. VEGF is known to have high affinity to VEGF receptors such as VEGFR-1 (Flt-1) and VEGFR-2 (KDR) and their co-expression in pathological condition had been demonstrated in previous studies. Papillary thyroid carcinoma (PTC) is the most common differentiated thyroid cancer and studies showed the increasing incidence of carcinoma arising in multinodular goitre (MNG). The aim of the current study to determine the expression of VEGF and VEGF receptors (VEGFR) in thyroid nodular hyperplasia and PTC. Materials and methods: We conducted a cross sectional study based on retrieved paraffinized archival tissue blocks of 113 nodular hyperplasia and 67 PTC from the thyroidectomy specimens from the year of 2003 to 2014.The tissue sections were then stained by immunohistochemistry for VEGF, VEGFR-1 and VEGFR-2. The lymph node involvement and extrathyroid extension also were determined. Results: The mean age of PTC patients was 44.7 ± 15.8years and nodular hyperplasia subjectswere42.2 ± 13.6years. Female gender predominate in both benign nodular hyperplasia and PTC with, 86% (97 out of 113) and 78% (52 out of67) respectively. There was a statistical difference of VEGFR-1 (p=0.028) andVEGFR-2 (p=0.003) expression between nodular hyperplasia and PTC. However, no significant difference of VEGF expression (p=0.576) between both diseases. Co-expression of VEGF and VEGFR-1 was significant in both nodular hyperplasia (p=0.016) and papillary thyroid carcinoma (p=0.03), meanwhile no relevant relationship for VEGF and VEGFR-2 expression (p>0.05). The patients were further divided into young age group (<45 years old) and older age group (≥45 years old). Most of the subjects positive for lymph node metastasis and had extrathyroid extension were female and from older age group. From 15 lymph nodes with metastasis, 60% (9/15) were female and 53% (8/15) from older age group. All two cases that showed extrathyroid extension were from older age group and female. However, there was no significant association (p>0.05) between lymph node status and extrathyroid extension with age groups, gender, VEGF and VEGFR expression. Conclusions: VEGF, VEGFR-1 and VEGFR-2 showed overexpression in both benign thyroid nodular hyperplasia and PTC. The expression of VEGFR-1 and VEGFR-2 more significant in PTC with relevant co-expression of VEGF and VEGFR-1. 2017 Thesis NonPeerReviewed application/pdf en http://eprints.usm.my/45422/1/Dr.%20Nurhidayati%20Mohamad%20Pakarul%20Razy-24%20pages.pdf Razy, Nur Hidayati Mohamad Pakarul (2017) Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC). Masters thesis, Universiti Sains Malaysia.
spellingShingle RC648-665 Diseases of the endocrine glands. Clinical endocrinology
Razy, Nur Hidayati Mohamad Pakarul
Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title_full Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title_fullStr Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title_full_unstemmed Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title_short Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title_sort expression of vascular endothelial growth factor vegf and its receptor vegfr in thyroid nodular hyperplasia and papillary thyroid carcinoma ptc
topic RC648-665 Diseases of the endocrine glands. Clinical endocrinology
url http://eprints.usm.my/45422/1/Dr.%20Nurhidayati%20Mohamad%20Pakarul%20Razy-24%20pages.pdf
work_keys_str_mv AT razynurhidayatimohamadpakarul expressionofvascularendothelialgrowthfactorvegfanditsreceptorvegfrinthyroidnodularhyperplasiaandpapillarythyroidcarcinomaptc